Claims
- 1. An isolated nucleic acid comprising a polynucleotide encoding a polypeptide at least 60% identical to SEQ ID NO:9.
- 2. The nucleic acid of claim 1, wherein the polynucleotide encodes SEQ ID NO:2.
- 3. The nucleic acid of claim 1, wherein the polynucleotide comprises SEQ ID NO:1.
- 4. The nucleic acid of claim 1, wherein the polynucleotide encodes SEQ ID NO:7.
- 5. The nucleic acid of claim 1, wherein the polynucleotide comprises SEQ ID NO:8
- 6. The nucleic acid of claim 1, wherein the polynucleotide encodes SEQ ID NO:6.
- 7. The nucleic acid of claim 1, wherein the polynucleotide comprises SEQ ID NO:5.
- 8. The nucleic acid of claim 1, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.
- 9. The nucleic acid of claim 1, wherein the nucleic acid is amplified using primers comprising SEQ ID NO:15 and SEQ ID NO:16.
- 10. An expression cassette comprising a promoter operably linked to the nucleic acid of claim 1.
- 11. An isolated nucleic acid that specifically hybridizes following at least one wash in 0.2×SSC at 55° C. for 20 minutes to a probe comprising SEQ ID NO:1.
- 12. An isolated polypeptide comprising an amino acid sequence at least 60% identical to SEQ ID NO:9.
- 13. The polypeptide of claim 12, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.
- 14. The polypeptide of claim 12, wherein the polypeptide comprises SEQ ID NO:2.
- 15. The polypeptide of claim 12, wherein the polypeptide comprises SEQ ID NO:6.
- 16. The polypeptide of claim 12, wherein the polypeptide specifically binds to antibodies generated against SEQ ID NO:9.
- 17. An antibody that specifically hybridizes to the polypeptide of claim 12.
- 18. A host cell transfected with the nucleic acid of claim 1.
- 19. The host cell of claim 1, wherein the cell is a pancreatic islet cell.
- 20. A pharmaceutical composition comprising insulin and a polypeptide at least 60% identical to SEQ ID NO:9.
- 21. The pharmaceutical composition of claim 20, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10,SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.
- 22. The pharmaceutical composition of claim 20, wherein the polypeptide comprises SEQ ID NO:2.
- 23. The pharmaceutical composition of claim 20, which is suitable for injection.
- 24. A method of diagnosing type 1 or type 2 diabetes or a predisposition for type 1 or type 2 diabetes in a patient, the method comprising,
detecting the level of a polypeptide at least 60% identical to SEQ ID NO:9 in a sample from the patient, wherein a modulated level of the polypeptide in the sample compared to a level of the polypeptide in a non-diabetic individual indicates that the patient is diabetic or is predisposed for at least some pathological aspects of diabetes.
- 25. The method of claim 24, wherein the modulated level of the polypeptide in the sample is lower than a level of the polypeptide in a non-diabetic individual.
- 26. The method of claim 24, wherein the modulated level of the polypeptide in the sample is higher than a level of the polypeptide in a non-diabetic individual.
- 27. The method of claim 24, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.
- 28. The method of claim 24, wherein the polypeptide comprises SEQ ID NO:2.
- 29. The method of claim 24, wherein the polypeptide is detected by an antibody.
- 30. The method of claim 25, wherein the level of the polypeptide in the patient is less than 50% of the level from the non-diabetic individual.
- 31. The method of claim 26, wherein the level of the polypeptide in the patient is at least 150% of the level from the non-diabetic individual.
- 32. A method of treating a patient diagnosed with type 1 or type 2 diabetes, the method comprising,
administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of an agonist of Archipelin and an agent that increases expression of Archipelin.
- 33. The method of claim 32, wherein the compound is an agonist of Archipelin.
- 34. The method of claim 32, wherein the compound is an agent that increases expression of Archipelin.
- 35. The method of claim 32, wherein the agonist is a polypeptide at least 60% identical to SEQ ID NO:9.
- 36. The method of claim 32, wherein the agonist comprises a polypeptide comprising SEQ ID NO:2.
- 37. The method of claim 32, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.
- 38. The method of claim 32, wherein the pharmaceutical composition comprises insulin.
- 39. The method of claim 32, wherein the pharmaceutical composition is administered parenterally.
- 40. The method of claim 39, wherein the pharmaceutical composition is administered by injection.
- 41. The method of claim 39, wherein the pharmaceutical composition is administered by a pump device.
- 42. A method of modulating Archipelin activity in a cell, the method comprising,
introducing into a pancreatic islet cell an expression cassette comprising a promoter operably linked to a polynucleotide encoding a polypeptide at least 60% identical to SEQ ID NO:9.
- 43. The method of claim 42, wherein the polypeptide comprises SEQ ID NO:2.
- 44. The method of claim 42, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.
- 45. The method of claim 42, wherein the cell is introduced into a patient.
- 46. The method of claim 45, wherein the cell is from the patient.
- 47. The method of claim 42, wherein the expression cassette is contained in a viral vector.
- 48. A method of identifying an agent useful for the treatment of diabetes, the method comprising,
contacting a cell with an agent; and selecting an agent that modulates the expression in the cell of a polypeptide at least 60% identical to SEQ ID NO:9.
- 49. The method of claim 48, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.
- 50. The method of claim 48, wherein the cell is from a diabetic animal.
- 51. The method of claim 50, wherein the diabetic animal is a human.
- 52. The method of claim 48, wherein the cell is a pancreatic islet cell.
- 53. The method of claim 48, wherein the polypeptide comprises SEQ ID NO:2.
- 54. The method of claim 48, wherein the expression of the polypeptide is increased following the contacting step.
- 55. A method of treating a patient diagnosed with type 1 or type 2 diabetes, the method comprising administering a therapeutically effective amount of an agent that was identified by the method of claim 48.
- 56. The method of claim 55, wherein the agent increases the expression of the polypeptide in the patient.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application No. 60/336,633, filed on Dec. 3, 2001, which is incorporated by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60336633 |
Dec 2001 |
US |